Physician profile
N Venugopal
NPI 1093883316
$1,015.46
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $197 · 2021: $221.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $369.77 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $154.31 | 2019 | |
| Lilly USA, LLC | $77.88 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $66.19 | 2019-2021 | |
| Pfizer INC. | $64.51 | 2020-2021 | |
| Philips North America LLC | $45.23 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $42.23 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.51 | 2020-2021 | |
| Amarin Pharma, INC. | $26.82 | 2019-2021 | |
| Glaxosmithkline, LLC. | $26.30 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $24.26 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $23.83 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.70 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.55 | 2019 | |
| Astellas Pharma US INC | $12.89 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $11.48 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw N Venugopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.